A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and C<sub>max</sub> Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities. [PDF]
Basic Clin Pharmacol ToxicolABSTRACT Angiotensin II (AngII) receptor blockers (ARBs) are medications that lower systolic blood pressure (BP) by antagonizing the AngII type 1 receptor (AT1). However, ARBs have documented or suspected therapeutic properties in diseases not caused by high BP including diabetes, muscular dystrophy, chronic obstructive pulmonary diseases (COPD) and ...
Evans A, Bernatchez P.
europepmc +2 more sources
Kidney & Blood Pressure Research, 2016 Background/Aims: Blockage of the renin-angiotensin II system (RAS) prevents or delays albuminuria in diabetic patients. The aim of this study was to investigate the inhibitory mechanism of the angiotensin receptor blocker olmesartan on albuminuria in a ...
Junhui Gu +14 more
doaj +1 more source
Molecular Static and Dynamic Analyses reveal Flaw in Murine Model used by US FDA to Detect Drug Carcinogenicity [PDF]
, 2007 The US FDA currently accepts carcinogenicity studies of pharmaceutical drugs based on murine models. In addition to 6 month studies with p53(+/-) and ras.H2 transgenic mice, lifetime studies (typically 2 years) in WT mice or rats are also considered as ...
Trevor Marshall
core +2 more sources
pharma-kritik, 2005 Der siebente Angiotensin-II-Rezeptorantagonist, nahe verwandt mit Losartan und ähnlich wirksam wie andere Sartane.
openaire +1 more source
Scientific Reports, 2023 Low dose aspirin is routinely taken with antihypertensive drugs such as olmesartan and metoprolol to avoid the cardiovascular and renal outcomes associated with high blood pressure. The first spectrofluorimetric method for quantifying aspirin, olmesartan,
Ali Alqahtani +3 more
doaj +1 more source
Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-long-evans-Tokushima Fatty rats [PDF]
, 2009 We investigated the impact of olmesartan and temocapril on pancreatic islet beta-cells during the development of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats.
Hanayama, Yoshihisa +6 more
core +1 more source
Sprue-Like Enteropathy and Liver Injury: A Rare Emerging Association with Olmesartan
Journal of Investigative Medicine High Impact Case Reports, 2021 Olmesartan-induced enteropathy is an underreported phenomenon, first described in 2012. While olmesartan’s antihypertensive properties were confirmed early on, its association with a sprue-like enteropathy was subsequently noted.
Mihir Odak MD +4 more
doaj +1 more source
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]
, 2017 Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig +15 more
core +1 more source
Journal of Chemistry, 2013 Olmesartan medoxomil (1) is the latest angiotensin receptor antagonist approved by the FDA for the treatment of hypertension. During the process development of olmesartan medoxomil, three process-related impurities were observed along with the final API.
G. Venkanna +5 more
doaj +1 more source
Pharmacological effects of raas blockade in ischemic nephropathy [PDF]
, 2016 Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio +8 more
core +1 more source